Connect with us


News You Might Have Missed – October 12, 2021

The article News You Might Have Missed – October 12, 2021 was originally published on Microdose.

Welcome to the News You Might Have Missed, a weekly…



The article News You Might Have Missed – October 12, 2021 was originally published on Microdose.

Welcome to the News You Might Have Missed, a weekly roundup of news items to help you catch up and stay informed.

It was a busy week with lots of news, have a look and see you next week for another update.

Cybin Files an International Patent Application Covering Psychedelic Delivery Methods
The company announced that it has filed an international patent application related to methods for the delivery of psychedelic medications by inhalation and devices for performing those methods. Read more

Silo Wellness’ Marley One Line of Functional Mushrooms Now Sold On Amazon
The company announced the listing of its portfolio of Marley One branded mushroom products on multinational e-commerce conglomerate Amazon. Read more

Levitee Labs Signs Letter of Intent to Acquire Calgary Addiction and Compounding Pharmacy
Levitee has signed a letter of intent to acquire 51% of the issued and outstanding shares in a compounding pharmacy in Calgary, Alberta, Canada. Read more

atai Life Sciences announces the launch of PsyProtix, to develop a precision psychiatry approach for Treatment-Resistant Depression (TRD)
Atai announced the launch of PsyProtix, a new platform company formed with Chymia LLC, a Duke University biotechnology spinout. PsyProtix is a precision psychiatry company focused on developing therapeutics for treatment-resistant depression (TRD) and other mental health indications. Read more

Psyched Wellness Announces Commencement of Next Pre-Clinical Study on AME-1
David Shisel, Chief Operating Officer of Psyched, said: “In conjunction with the other studies the Company is conducting, this trial will bolster Psyched’s toxicological assessment of AME-1 and provide critical knowledge of any behavioral and neurological functional changes in a scientific setting. This is another key step in determining a safe dose of AME-1 for human consumption and moves Psyched closer to being able to bring our Amanita-based CPG products to market.” Read more

Psygen Announces use of Psilocybin in Human Trial and Provides Update on IP Portfolio
Psygen is excited to announce that psilocybin recently used in a clinical trial was manufactured by Psygen personnel working with a third-party licensed dealer. The Company is also announcing that Psygen has developed patent-pending technology that is expected to improve yields and margins on revenue, and that the technology is key to scale-up and automation. Read More

Read More